Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B
Takahiro Uehara, … , Max D. Cooper, Hiromi Kubagawa
Takahiro Uehara, … , Max D. Cooper, Hiromi Kubagawa
Published October 1, 2001
Citation Information: J Clin Invest. 2001;108(7):1041-1050. https://doi.org/10.1172/JCI12195.
View: Text | PDF
Article

Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B

  • Text
  • PDF
Abstract

The potential of the paired Ig-like receptors of activating (PIR-A) and inhibitory (PIR-B) types for modifying an IgE antibody–mediated allergic response was evaluated in mouse bone marrow–derived mast cells. Although mast cells produced both PIR-A and PIR-B, PIR-B was found to be preferentially expressed on the cell surface, where it was constitutively tyrosine phosphorylated and associated with intracellular SHP-1 protein tyrosine phosphatase. PIR-B coligation with the IgE receptor (FcεRI) inhibited IgE-mediated mast cell activation and release of serotonin. Surprisingly, the inhibitory activity of PIR-B was unimpaired in SHP-1–deficient mast cells. A third functional tyrosine-based inhibitory motif, one that fails to bind the SHP-1, SHP-2, and SHIP phosphatases, was identified in parallel studies of FcεRI-bearing rat basophilic leukemia (RBL) cells transfected with constructs having mutations in the PIR-B cytoplasmic region. These results define the preferential expression of the PIR-B molecules on mast cells and an inhibitory potential that can be mediated via a SHP-1–independent pathway.

Authors

Takahiro Uehara, Mathieu Bléry, Dong-Won Kang, Ching-Cheng Chen, Le Hong Ho, G. Larry Gartland, Fu-Tong Liu, Eric Vivier, Max D. Cooper, Hiromi Kubagawa

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Cell surface expression of PIR molecules on cultured mast cells. Nonadhe...
Cell surface expression of PIR molecules on cultured mast cells. Nonadherent cells from the bone marrow of (a) wild-type mice (C57BL/cJ) and (b) FcεRIα–/– mice and from the neonatal spleens of (c) wild-type mice (C3H/HeJ) and (d) me/me mice were cultured for 6 weeks with rIL-3. Cells were sequentially incubated with the PE-labeled 6C1 anti-PIR mAb, biotinylated ACK-2 anti–c-kit mAb, and APC-labeled streptavidin or with rat IgE anti-DNP mAb (dark histogram) and FITC-labeled goat anti-rat Ig antibodies before analysis by flow cytometry. Isotype-matched control rat mAb’s were used to set the quadrants for immunofluorescence analysis, and unstained background controls are indicated by open histograms.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts